DK1216032T3 - Orale formuleringer med kontrolleret frigivelse - Google Patents

Orale formuleringer med kontrolleret frigivelse

Info

Publication number
DK1216032T3
DK1216032T3 DK00971290T DK00971290T DK1216032T3 DK 1216032 T3 DK1216032 T3 DK 1216032T3 DK 00971290 T DK00971290 T DK 00971290T DK 00971290 T DK00971290 T DK 00971290T DK 1216032 T3 DK1216032 T3 DK 1216032T3
Authority
DK
Denmark
Prior art keywords
controlled
oral formulations
release oral
release
formulations
Prior art date
Application number
DK00971290T
Other languages
Danish (da)
English (en)
Inventor
Satish Chandra Khanna
Joerg Ogorka
Rajen Shah
Oskar Kalb
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10861819&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1216032(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Application granted granted Critical
Publication of DK1216032T3 publication Critical patent/DK1216032T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK00971290T 1999-09-29 2000-09-27 Orale formuleringer med kontrolleret frigivelse DK1216032T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9923045.0A GB9923045D0 (en) 1999-09-29 1999-09-29 New oral formulations
PCT/EP2000/009455 WO2001022944A1 (en) 1999-09-29 2000-09-27 Oral controlled release formulations

Publications (1)

Publication Number Publication Date
DK1216032T3 true DK1216032T3 (da) 2008-06-02

Family

ID=10861819

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00971290T DK1216032T3 (da) 1999-09-29 2000-09-27 Orale formuleringer med kontrolleret frigivelse

Country Status (31)

Country Link
US (2) US20060246101A1 (es)
EP (1) EP1216032B1 (es)
JP (1) JP2003510268A (es)
KR (2) KR20050100710A (es)
CN (1) CN1213737C (es)
AR (1) AR025792A1 (es)
AT (1) ATE384517T1 (es)
AU (1) AU769646B2 (es)
BR (1) BR0014440A (es)
CA (1) CA2379595A1 (es)
CO (1) CO5210867A1 (es)
CY (1) CY1107923T1 (es)
CZ (1) CZ301455B6 (es)
DE (1) DE60037897T2 (es)
DK (1) DK1216032T3 (es)
EC (1) ECSP003685A (es)
ES (1) ES2299438T3 (es)
GB (1) GB9923045D0 (es)
HU (1) HUP0202744A3 (es)
IL (2) IL148908A0 (es)
MY (1) MY128759A (es)
NO (1) NO331480B1 (es)
NZ (1) NZ517335A (es)
PE (1) PE20010568A1 (es)
PL (1) PL200822B1 (es)
PT (1) PT1216032E (es)
RU (1) RU2281758C2 (es)
SK (1) SK286651B6 (es)
TR (1) TR200200683T2 (es)
WO (1) WO2001022944A1 (es)
ZA (1) ZA200202369B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY142204A (en) 2002-07-25 2010-10-29 Pharmacia Corp Pramipexole once-daily dosage form
CN101005830B (zh) 2004-08-13 2010-09-29 贝林格尔·英格海姆国际有限公司 包含普拉克索或其可药用盐的延长释放片剂、其制备方法及用途
NZ553645A (en) * 2004-08-13 2010-09-30 Boehringer Ingelheim Int Extended release pellet formulation containing pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof
US8481565B2 (en) * 2004-12-27 2013-07-09 Eisai R&D Management Co., Ltd. Method for stabilizing anti-dementia drug
GB0606562D0 (en) * 2006-03-31 2006-05-10 Novartis Ag Organic compounds
CN101797236B (zh) * 2010-03-23 2012-05-23 西南大学 重酒石酸卡巴拉汀口腔崩解片及其制备方法
JP6173912B2 (ja) 2010-09-20 2017-08-02 エスピーアイ ファーマ，インコーポレイテッド マイクロカプセル化プロセスおよび製品
KR101990951B1 (ko) 2015-04-27 2019-06-20 주식회사 네비팜 리바스티그민 함유 서방출 의약조성물
CN106000294B (zh) * 2016-07-04 2019-04-30 三峡大学 一种高膨胀低收缩率膨润土及制备方法
CN115192538B (zh) * 2022-08-02 2023-09-15 沈阳信康药物研究有限公司 一种压制包衣型硝苯地平缓释片及其制备方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8404467D0 (sv) * 1984-09-06 1984-09-06 Ferrosan Ab Controlled-release medical preparations
IL74497A (en) * 1985-03-05 1990-02-09 Proterra Ag Pharmaceutical compositions containing phenyl carbamate derivatives and certain phenyl carbamate derivatives
NL195004C (nl) * 1987-03-04 2003-11-04 Novartis Ag Fenylcarbamaat bevattend farmaceutisch preparaat.
DE3805744C2 (de) * 1987-03-04 1999-09-23 Novartis Ag Phenylcarbamate zur Hemmung der Acetylcholinesterase
US4984807A (en) * 1990-01-12 1991-01-15 Baruch Shiryon Board game
US5229131A (en) * 1990-02-05 1993-07-20 University Of Michigan Pulsatile drug delivery system
EP0542926B1 (en) * 1990-08-07 1995-02-15 Pfizer Inc. Use of interfacially-polymerized membranes in delivery devices
US5407686A (en) * 1991-11-27 1995-04-18 Sidmak Laboratories, Inc. Sustained release composition for oral administration of active ingredient
US5260069A (en) * 1992-11-27 1993-11-09 Anda Sr Pharmaceuticals Inc. Pulsatile particles drug delivery system
US5358502A (en) * 1993-02-25 1994-10-25 Pfizer Inc PH-triggered osmotic bursting delivery devices
DE69425453T2 (de) * 1993-04-23 2001-04-12 Novartis Ag, Basel Wirkstoffabgabevorrichtung mit gesteuerter Freigabe
US5500227A (en) * 1993-11-23 1996-03-19 Euro-Celtique, S.A. Immediate release tablet cores of insoluble drugs having sustained-release coating
US5962535A (en) * 1997-01-17 1999-10-05 Takeda Chemical Industries, Ltd. Composition for alzheimer's disease
AU7706598A (en) * 1997-05-30 1998-12-30 Laboratorios Phoenix U.S.A., Inc. Multi-layered osmotic device
GB9711643D0 (en) * 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
IL152330A0 (en) * 1997-07-01 2003-05-29 Pfizer Sertraline salts and sustained-release dosage forms of sertraline
SE9704870D0 (sv) * 1997-12-22 1997-12-22 Astra Ab New pharmaceutical formulation I
PT1121104E (pt) * 1998-10-01 2005-05-31 Novartis Ag Novas formulacoes orais de libertacao controlada
US6632451B2 (en) * 1999-06-04 2003-10-14 Dexcel Pharma Technologies Ltd. Delayed total release two pulse gastrointestinal drug delivery system

Also Published As

Publication number Publication date
CN1376058A (zh) 2002-10-23
CO5210867A1 (es) 2002-10-30
US20060246101A1 (en) 2006-11-02
DE60037897T2 (de) 2008-12-24
EP1216032B1 (en) 2008-01-23
BR0014440A (pt) 2002-06-18
CZ20021028A3 (cs) 2002-06-12
SK286651B6 (sk) 2009-03-05
HUP0202744A3 (en) 2004-05-28
AU1019701A (en) 2001-04-30
SK4132002A3 (en) 2002-10-08
WO2001022944A1 (en) 2001-04-05
IL148908A0 (en) 2002-09-12
ECSP003685A (es) 2002-05-23
ATE384517T1 (de) 2008-02-15
NO331480B1 (no) 2012-01-16
TR200200683T2 (tr) 2002-07-22
AU769646B2 (en) 2004-01-29
AR025792A1 (es) 2002-12-11
PL354075A1 (en) 2003-12-15
ZA200202369B (en) 2002-12-24
IL148908A (en) 2010-06-16
GB9923045D0 (en) 1999-12-01
CA2379595A1 (en) 2001-04-05
KR20050100710A (ko) 2005-10-19
NO20021452D0 (no) 2002-03-22
CN1213737C (zh) 2005-08-10
DE60037897D1 (de) 2008-03-13
CZ301455B6 (cs) 2010-03-10
EP1216032A1 (en) 2002-06-26
CY1107923T1 (el) 2013-09-04
PT1216032E (pt) 2008-04-29
US20110038897A1 (en) 2011-02-17
ES2299438T3 (es) 2008-06-01
KR20020038778A (ko) 2002-05-23
RU2281758C2 (ru) 2006-08-20
JP2003510268A (ja) 2003-03-18
NO20021452L (no) 2002-03-22
PL200822B1 (pl) 2009-02-27
NZ517335A (en) 2003-10-31
HUP0202744A2 (hu) 2003-01-28
PE20010568A1 (es) 2001-05-29
MY128759A (en) 2007-02-28
KR100661441B1 (ko) 2006-12-27
WO2001022944A8 (en) 2001-07-26

Similar Documents

Publication Publication Date Title
DE122008000001I1 (de) Orale Dosiszusammensetzungen mit verlängerter Freigabe
AR026045A1 (es) Formulaciones de liberacion prolongada de derivados de eritromocina
ID23299A (id) Formulasi-formulasi farmasi
DE60109207T8 (de) Orale zusammensetzung
IS5555A (is) Selekoxib lyfjablöndur
ID30031A (id) Formulasi-formulasi agrokimia
ID23546A (id) Formulasi-formulasi ziprasidon
NO993096D0 (no) Orale cyklosporinformuleringer
NO20004240D0 (no) Formuleringer
DK1237408T3 (da) Hæld-på-formuleringer
DE60218175D1 (de) Stabilisierte orale suspensionsformulierung
NO20021834L (no) Orale formuleringer av anti-tumorforbindelser
DE60007530D1 (de) Oral wirksame androgene
NO20015670L (no) Forbedrede farmasöytiske formuleringer
DE10196204T1 (de) Orale Vorrichtungen
IS6398A (is) Lyfjablöndur
EE05375B1 (et) LevosimendaniÁfarmatseutilineÁlahus
ITMI991826A0 (it) Nuova formulazione orale
PT868911E (pt) Formulacoes de rapamicina para administracao oral
DE60326998D1 (de) Orale zubereitung
DK1216032T3 (da) Orale formuleringer med kontrolleret frigivelse
NO996044L (no) Rapamycinformuleringer for oral administrasjon
ID30397A (id) Larutan oral prukaloprida
IT1313594B1 (it) Bisplatino complessi attivi per via orale.
FR2790382B1 (fr) Articulateur dentaire